Tests C14 in women with persistent HPV infection and early cervical cell changes
Tests whether C14 reduces HPV in women with cervical cell changes.
Plain-language title generated from the registry record
Registry title: Tolerance and Effectiveness of C14 on HPV Infection
Key facts
- Where
- Bunia, Congo - KinshasaSee the site
- Phase
- Phase 1/2
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for sexually active women aged 30 to 65 with a lasting high-risk HPV infection. It tests whether C14 lowers the HPV load and treats mild cervical changes.
- Age
- 30 to 65 years
- Sex
- Women only
- Disease stage
- The record mentions persistent high-risk HPV infection and low-grade cervical lesions.
- Earlier treatment
- Women with previous cervical surgery or who took or used other antivirals cannot join.
- Biomarker or test result
- Persistent high-risk (oncogenic) HPV infection.
Main reasons for not taking part
- Pregnant, breastfeeding or post-partum women
- Previous cervical surgery
- History of any severe disease
- Taking or using other antivirals
- Known or suspected allergy to C14 or its components
Read by machine on 12 November 2026.
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 30 and 65 years old?
Source: NCT06672653, who can take part
Where in Congo - Kinshasa
- Polyclinique CitadelleBunia, Congo - KinshasaContact: Serge TONEN WOLYECNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- MGB Pharma
- Trial code
- NCT06672653
- Record updated
- 4 November 2024
- Original description
The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug.Read full original descriptionShow less
PREPAP Study: Tolerance and Effectiveness of the Monoterpenoid Zinc Tetra-ascorbo-camphorate (C14) on the Genital Load of Oncogenic HPV (HR-HPV) and Precancerous Cervical Lesions: Research With Direct Individual Benefit
The zinc monoterpenoid tetra-ascorbo-camphorate possesses broad-spectrum anti-viral properties in vitro, particularly against HIV, HSV and HPV. Its C14 formulation could be a promising candidate for in vivo clinical evaluation as a potential microbicide or therapeutic drug.
The aim of this clinical trial is to determine whether C14 is effective in reducing the genital viral load of HR-HPV and in treating low-grade dysplastic lesions of the cervix. It will also determine the tolerability of C14. The main questions to be answered by the clinical trial are as follows:
Does C14 reduce the genital HR-HPV viral load in participants with persistent HR-HPV infections? What medical problems do participants experience when taking C14? Researchers will compare C14 to a placebo (a similar substance that contains no drug) to see if C14 is effective in reducing genital C14 viral load and in treating low-grade dysplastic lesions of the cervix.
Participants will
receive four monthly treatments (5ml of C14 dissolved in distilled water administered twice daily [morning and evening] for seven days via vaginal syringe during the follicular phase) of C14 or placebo for 4 months and visit the clinic once every 2 weeks for examinations and tests. They will keep a diary of their symptoms and the number of times they keep the hospital appointment.
Inclusion: sexually-active women; aged at least 30 years old; who will give their informed consent to participate in the study.
Exclusion: previous cervical surgery, medical history of any severe diseases, intake or application of other antivirals; known or suspected allergic or adverse response to the investigational product or its components; Pregnant; breastfeeding and post-partum women will not be accepted in the study; women who are unable to follow the study protocol.